Family Medicine

Top Story

Biologic therapy not cost-effective for RA after methotrexate fails

May 29, 2017

Initiating biologic therapy in patients with rheumatoid arthritis when methotrexate monotherapy fails increases costs substantially and provides minimal incremental benefit compared with triple therapy, according to data published in Annals of Internal Medicine.

The researchers suggest that triple therapy be used first before switching to a biologic strategy because it could reduce patients’ out-of-pocket costs and not expose them to serious side effects associated with biologic therapy.

In the Journals Plus

Decline in cervical lesions driven by HPV vaccination

May 28, 2017
Age and cohort patterns seen in recent data showed that declines in high-grade cervical lesions among young women are likely driven by HPV vaccination, not changes in…
In the Journals

Racial residential segregation associated with systolic BP changes

May 26, 2017
A reduction in exposure to racial residential segregation was linked to lower systolic BP, according to a study in JAMA Internal Medicine. “Our study suggests…
FDA News

FDA expands approval of Zykadia for ALK–positive metastatic NSCLC

May 26, 2017
The FDA expanded the approval of ceritinib to include the first-line treatment of patients with metastatic non–small cell lung cancer, according to the…
More News Headlines »
CME

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

This activity is supported by an educational grant from Shire.

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis…
More »
GI Bookshelf

Chapter 3: Barrier Function And Theimmune Response

From Probiotics: A Clinical Guide
More »
Featured
American Academy of Allergy, Asthma & Immunology Annual Meeting

American Academy of Allergy, Asthma & Immunology Annual Meeting

Video
Meeting News

VIDEO: As telemedicine expands, ethical issues arise, impede progress

May 10, 2017
More »
Advertisement
Advertisement